Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | KDM4A | O75164 | 2/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TGM1 | P22735 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392019 | 0.99 | HTT (0.50) | HTTCCR6PAX8ALOX5ALDH1A1 | |
| SCHEMBL28002371 | 0.99 | HTT (0.50) | HTTCCR6PAX8ALOX5ALDH1A1 | |
| SCHEMBL393422 | 0.95 | HTT (0.52) | HTTCCR6PAX8ALOX5ALDH1A1 | |
| SCHEMBL21235957 | 0.90 | CCR6 (0.48) | CCR6PAX8ALDH1A1MAPTBCHE | |
| SCHEMBL164180 | 0.89 | ALDH1A1 (0.51) | HTTCCR6PAX8ALDH1A1MAPT | |
| SCHEMBL392184 | 0.89 | ALDH1A1 (0.49) | HTTCCR6PAX8ALDH1A1MAPT | |
| SCHEMBL9684805 | 0.87 | ALDH1A1 (0.47) | CCR6PAX8ALDH1A1MAPTBCHE | |
| SCHEMBL21235941 | 0.87 | ABCB1 (0.50) | CCR6PAX8ALDH1A1MAPTBCHE | |
| SCHEMBL392903 | 0.87 | ALDH1A1 (0.47) | CCR6PAX8ALDH1A1MAPTBCHE | |
| SCHEMBL19346032 | 0.87 | CCR6 (0.53) | CCR6PAX8ALDH1A1MAPTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311880-B | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3478680-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-22 | — | — | EP | disclosed |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| CN-109311880-A | For treating and preventing hepatitis b virus infected new tetrahydropyridine miazines compound | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-8334284-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-12 | — | — | US | disclosed |
| US-8101601-B2 | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | BAYER HELTHCARE AG | 2011-02-10 | — | — | US | disclosed |
| EP-2167500-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| EP-1987026-B1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER HEALTHCARE AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009007028-A1 | PRODRUG DERIVATIVES OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007027-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| EP-1987026-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | Bayer HealthCare AG (DE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093328-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088761-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR THE TREATMENT OF THROMBOEMBOLITIC DISORDERS | PLG, AADAC, DNPEP | HTT 3486/4885CCR6 4038/4885PAX8 4517/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | HTT 3937/4885CCR6 4647/4885PAX8 4630/4885 |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | TYMP, RECQL, DPYD | HTT 3348/4885CCR6 937/4885PAX8 3520/4885 |
| US-20110034453-A1 | Aminoacyl Prodrug Derivatives and Medicaments for the Treatment of Thromboembolitic Disorders | PLG, AADAC, DNPEP | HTT 3486/4885CCR6 4038/4885PAX8 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.